# A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

> **NCT02742519** · PHASE3 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 14 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ivacaftor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02742519
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Low enrollment.
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02742519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02742519, "A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02742519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*